The need for flawless coordination of its carbon ion treatments led officials at the CNAO Foundation (Centro Nazionale di Adroterapia Oncologica) to choose Elekta’s Mosaiq Oncology Information Management System. On Nov. 13, the CNAO Foundation became the world’s first center to use Mosaiq to guide a cancer patient’s carbon ion therapy. CNAO — which made news last year when it treated its first patient with proton therapy — is now nearing completion of its National Center of Oncological Hadrontherapy.

Agfa HealthCare has introduced its global remote incident prevention (GRIP) services to provide state-of-the-art electronic monitoring of all IMPAX picture archiving and communication systems (PACS) worldwide, as well as linked devices from other suppliers. GRIP’s ultimate goal is to prevent unsettling downtime surprises in the healthcare environment.

3Flow Aspiration Catheter

PhysioSonics announced the U.S. Food and Drug Administration (FDA) has granted the Presto 1000 Flow Monitor system 510(k) clearance for cranial blood flow monitoring. In addition, the company announced completion of Series B add-on debt financing, closing with $1.05 million.

 

February 1, 2013 — SoftVue, the whole breast ultrasound device created by two scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, is currently undergoing review by the U.S. Food and Drug Administration (FDA) for market clearance.

A patient's relationship with his or her doctor has long been considered an important component of healing. Now, in a novel investigation in which physicians underwent brain scans while they believed they were actually treating patients, researchers have provided the first scientific evidence indicating that doctors truly can feel their patients' pain — and can also experience their relief following treatment.

February 1, 2013 — Six clinical trials, including one evaluating the effectiveness of proton beam therapy in treating children with specific brain cancers and three proton therapy trials for men with prostate cancer, are being led by researchers at CDH Proton Center, A ProCure Center.

Accu-Tatt is an easy-to-use, sterile, all inclusive tattooing device designed to permanently mark radiation therapy patients. Every Accu-Tatt pouch conveniently contains an ink ampoule and a ¾-inch, 22-gauge needle. Packaging the needle and ampoule in a sterilized pouch reduces the concern for contamination and cross-contamination within radiation therapy facilities. In addition, Accu-Tatt’s short needle length allows for increased control while tattooing the patient. The Accu-Tatt shell contains an ampoule filled with sterile black ink. To start the flow of ink, hold the ampoule upright in one hand and use the thumb to bend the shell, breaking the ampoule. The end of the ampoule houses a luer lock fitting to accommodate the prepackaged, sterilized hypodermic needle.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now